Principal Investigator: Ronald Gentile, M.D.
Enrollment Status: Completed
Objective: To determine the safety of LY333531, any side effects that might be associated with it, and whether or not LY333531 can help prevent the progression of eye disease or visual loss in patients with diabetic eye disease. This is a phase III clinical trial.
CONCLUSION: Oral ruboxistaurin treatment reduced the occurrence of sustained moderate visual loss by 40% and increased vision improvement two-fold in patients with advanced nonproliferative diabetic retinopathy.
For more information: